Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 333

1.

Association of microRNA-7 and its binding partner CDR1-AS with the prognosis and prediction of 1st-line tamoxifen therapy in breast cancer.

Uhr K, Sieuwerts AM, de Weerd V, Smid M, Hammerl D, Foekens JA, Martens JWM.

Sci Rep. 2018 Jun 25;8(1):9657. doi: 10.1038/s41598-018-27987-w.

2.

Gene length corrected trimmed mean of M-values (GeTMM) processing of RNA-seq data performs similarly in intersample analyses while improving intrasample comparisons.

Smid M, Coebergh van den Braak RRJ, van de Werken HJG, van Riet J, van Galen A, de Weerd V, van der Vlugt-Daane M, Bril SI, Lalmahomed ZS, Kloosterman WP, Wilting SM, Foekens JA, IJzermans JNM; MATCH study group, Martens JWM, Sieuwerts AM.

BMC Bioinformatics. 2018 Jun 22;19(1):236. doi: 10.1186/s12859-018-2246-7.

3.

Tumor-Specific Mitochondrial DNA Variants Are Rarely Detected in Cell-Free DNA.

Weerts MJA, Timmermans EC, van de Stolpe A, Vossen RHAM, Anvar SY, Foekens JA, Sleijfer S, Martens JWM.

Neoplasia. 2018 Jul;20(7):687-696. doi: 10.1016/j.neo.2018.05.003. Epub 2018 May 26.

4.

The Prevalence of CD146 Expression in Breast Cancer Subtypes and Its Relation to Outcome.

de Kruijff IE, Timmermans AM, den Bakker MA, Trapman-Jansen AMAC, Foekens R, Meijer-Van Gelder ME, Oomen-de Hoop E, Smid M, Hollestelle A, van Deurzen CHM, Foekens JA, Martens JWM, Sleijfer S.

Cancers (Basel). 2018 May 5;10(5). pii: E134. doi: 10.3390/cancers10050134.

5.

Confirmation of a metastasis-specific microRNA signature in primary colon cancer.

Coebergh van den Braak RRJ, Sieuwerts AM, Lalmahomed ZS, Smid M, Wilting SM, Bril SI, Xiang S, van der Vlugt-Daane M, de Weerd V, van Galen A, Biermann K, van Krieken JHJM, Kloosterman WP, Foekens JA; MATCH study group*, Martens JWM, IJzermans JNM.

Sci Rep. 2018 Mar 27;8(1):5242. doi: 10.1038/s41598-018-22532-1.

6.

T lymphocytes facilitate brain metastasis of breast cancer by inducing Guanylate-Binding Protein 1 expression.

Mustafa DAM, Pedrosa RMSM, Smid M, van der Weiden M, de Weerd V, Nigg AL, Berrevoets C, Zeneyedpour L, Priego N, Valiente M, Luider TM, Debets R, Martens JWM, Foekens JA, Sieuwerts AM, Kros JM.

Acta Neuropathol. 2018 Apr;135(4):581-599. doi: 10.1007/s00401-018-1806-2. Epub 2018 Jan 19.

7.

The Predictive Value of PITX2 DNA Methylation for High-Risk Breast Cancer Therapy: Current Guidelines, Medical Needs, and Challenges.

Aubele M, Schmitt M, Napieralski R, Paepke S, Ettl J, Absmaier M, Magdolen V, Martens J, Foekens JA, Wilhelm OG, Kiechle M.

Dis Markers. 2017;2017:4934608. doi: 10.1155/2017/4934608. Epub 2017 Sep 12. Review.

8.

Estrogen receptor mutations and splice variants determined in liquid biopsies from metastatic breast cancer patients.

Beije N, Sieuwerts AM, Kraan J, Van NM, Onstenk W, Vitale SR, van der Vlugt-Daane M, Dirix LY, Brouwer A, Hamberg P, de Jongh FE, Jager A, Seynaeve CM, Jansen MPHM, Foekens JA, Martens JWM, Sleijfer S.

Mol Oncol. 2018 Jan;12(1):48-57. doi: 10.1002/1878-0261.12147. Epub 2017 Nov 17.

9.

High mRNA expression of splice variant SYK short correlates with hepatic disease progression in chemonaive lymph node negative colon cancer patients.

Coebergh van den Braak RRJ, Sieuwerts AM, Kandimalla R, Lalmahomed ZS, Bril SI, van Galen A, Smid M, Biermann K, van Krieken JHJM, Kloosterman WP, Foekens JA, Goel A, Martens JWM, IJzermans JNM; MATCH study group.

PLoS One. 2017 Sep 28;12(9):e0185607. doi: 10.1371/journal.pone.0185607. eCollection 2017.

10.

Phosphoserine aminotransferase 1 is associated to poor outcome on tamoxifen therapy in recurrent breast cancer.

De Marchi T, Timmermans MA, Sieuwerts AM, Smid M, Look MP, Grebenchtchikov N, Sweep FCGJ, Smits JG, Magdolen V, van Deurzen CHM, Foekens JA, Umar A, Martens JW.

Sci Rep. 2017 May 18;7(1):2099. doi: 10.1038/s41598-017-02296-w.

11.

A Systematic Analysis of Oncogenic Gene Fusions in Primary Colon Cancer.

Kloosterman WP, Coebergh van den Braak RRJ, Pieterse M, van Roosmalen MJ, Sieuwerts AM, Stangl C, Brunekreef R, Lalmahomed ZS, Ooft S, van Galen A, Smid M, Lefebvre A, Zwartkruis F, Martens JWM, Foekens JA, Biermann K, Koudijs MJ, Ijzermans JNM, Voest EE.

Cancer Res. 2017 Jul 15;77(14):3814-3822. doi: 10.1158/0008-5472.CAN-16-3563. Epub 2017 May 16.

12.

Low Tumor Mitochondrial DNA Content Is Associated with Better Outcome in Breast Cancer Patients Receiving Anthracycline-Based Chemotherapy.

Weerts MJA, Hollestelle A, Sieuwerts AM, Foekens JA, Sleijfer S, Martens JWM.

Clin Cancer Res. 2017 Aug 15;23(16):4735-4743. doi: 10.1158/1078-0432.CCR-17-0032. Epub 2017 Apr 18.

PMID:
28420722
13.

Variant peptide detection utilizing mass spectrometry: laying the foundations for proteogenomic identification and validation.

Dimitrakopoulos L, Prassas I, Berns EMJJ, Foekens JA, Diamandis EP, Charames GS.

Clin Chem Lab Med. 2017 Aug 28;55(9):1291-1304. doi: 10.1515/cclm-2016-0947.

PMID:
28157690
14.

Proteomic characterization of microdissected breast tissue environment provides a protein-level overview of malignant transformation.

Braakman RB, Stingl C, Tilanus-Linthorst MM, van Deurzen CH, Timmermans MA, Smid M, Foekens JA, Luider TM, Martens JW, Umar A.

Proteomics. 2017 Mar;17(5). doi: 10.1002/pmic.201600213.

15.

Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor.

Beije N, Onstenk W, Kraan J, Sieuwerts AM, Hamberg P, Dirix LY, Brouwer A, de Jongh FE, Jager A, Seynaeve CM, Van NM, Foekens JA, Martens JW, Sleijfer S.

Neoplasia. 2016 Nov;18(11):647-653. doi: 10.1016/j.neo.2016.08.007. Epub 2016 Oct 17.

16.

The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer.

Law EK, Sieuwerts AM, LaPara K, Leonard B, Starrett GJ, Molan AM, Temiz NA, Vogel RI, Meijer-van Gelder ME, Sweep FC, Span PN, Foekens JA, Martens JW, Yee D, Harris RS.

Sci Adv. 2016 Oct 7;2(10):e1601737. eCollection 2016 Oct.

17.

Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration.

Smid M, Rodríguez-González FG, Sieuwerts AM, Salgado R, Prager-Van der Smissen WJ, Vlugt-Daane MV, van Galen A, Nik-Zainal S, Staaf J, Brinkman AB, van de Vijver MJ, Richardson AL, Fatima A, Berentsen K, Butler A, Martin S, Davies HR, Debets R, Gelder ME, van Deurzen CH, MacGrogan G, Van den Eynden GG, Purdie C, Thompson AM, Caldas C, Span PN, Simpson PT, Lakhani SR, Van Laere S, Desmedt C, Ringnér M, Tommasi S, Eyford J, Broeks A, Vincent-Salomon A, Futreal PA, Knappskog S, King T, Thomas G, Viari A, Langerød A, Børresen-Dale AL, Birney E, Stunnenberg HG, Stratton M, Foekens JA, Martens JW.

Nat Commun. 2016 Sep 26;7:12910. doi: 10.1038/ncomms12910.

18.

Prognostic significance of nuclear expression of UMP-CMP kinase in triple negative breast cancer patients.

Liu NQ, De Marchi T, Timmermans A, Trapman-Jansen AM, Foekens R, Look MP, Smid M, van Deurzen CH, Span PN, Sweep FC, Brask JB, Timmermans-Wielenga V, Foekens JA, Martens JW, Umar A.

Sci Rep. 2016 Aug 25;6:32027. doi: 10.1038/srep32027.

19.

The 29.5 kb APOBEC3B Deletion Polymorphism Is Not Associated with Clinical Outcome of Breast Cancer.

Liu J, Sieuwerts AM, Look MP, van der Vlugt-Daane M, Meijer-van Gelder ME, Foekens JA, Hollestelle A, Martens JW.

PLoS One. 2016 Aug 23;11(8):e0161731. doi: 10.1371/journal.pone.0161731. eCollection 2016.

20.

Recurrent HOXB13 mutations in the Dutch population do not associate with increased breast cancer risk.

Liu J, Prager-van der Smissen WJ, Schmidt MK, Collée JM, Cornelissen S, Lamping R, Nieuwlaat A, Foekens JA, Hooning MJ, Verhoef S, van den Ouweland AM, Hogervorst FB, Martens JW, Hollestelle A.

Sci Rep. 2016 Jul 18;6:30026. doi: 10.1038/srep30026.

21.

Molecular characteristics of circulating tumor cells resemble the liver metastasis more closely than the primary tumor in metastatic colorectal cancer.

Onstenk W, Sieuwerts AM, Mostert B, Lalmahomed Z, Bolt-de Vries JB, van Galen A, Smid M, Kraan J, Van M, de Weerd V, Ramírez-Moreno R, Biermann K, Verhoef C, Grünhagen DJ, IJzermans JN, Gratama JW, Martens JW, Foekens JA, Sleijfer S.

Oncotarget. 2016 Sep 13;7(37):59058-59069. doi: 10.18632/oncotarget.10175.

22.

Cell-free DNA mutations as biomarkers in breast cancer patients receiving tamoxifen.

Jansen MP, Martens JW, Helmijr JC, Beaufort CM, van Marion R, Krol NM, Monkhorst K, Trapman-Jansen AM, Meijer-van Gelder ME, Weerts MJ, Ramirez-Ardila DE, Dubbink HJ, Foekens JA, Sleijfer S, Berns EM.

Oncotarget. 2016 Jul 12;7(28):43412-43418. doi: 10.18632/oncotarget.9727.

23.

Endocrine therapy resistance in estrogen receptor (ER)-positive breast cancer.

De Marchi T, Foekens JA, Umar A, Martens JW.

Drug Discov Today. 2016 Jul;21(7):1181-8. doi: 10.1016/j.drudis.2016.05.012. Epub 2016 May 24. Review.

PMID:
27233379
24.

Landscape of somatic mutations in 560 breast cancer whole-genome sequences.

Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, Martincorena I, Alexandrov LB, Martin S, Wedge DC, Van Loo P, Ju YS, Smid M, Brinkman AB, Morganella S, Aure MR, Lingjærde OC, Langerød A, Ringnér M, Ahn SM, Boyault S, Brock JE, Broeks A, Butler A, Desmedt C, Dirix L, Dronov S, Fatima A, Foekens JA, Gerstung M, Hooijer GK, Jang SJ, Jones DR, Kim HY, King TA, Krishnamurthy S, Lee HJ, Lee JY, Li Y, McLaren S, Menzies A, Mustonen V, O'Meara S, Pauporté I, Pivot X, Purdie CA, Raine K, Ramakrishnan K, Rodríguez-González FG, Romieu G, Sieuwerts AM, Simpson PT, Shepherd R, Stebbings L, Stefansson OA, Teague J, Tommasi S, Treilleux I, Van den Eynden GG, Vermeulen P, Vincent-Salomon A, Yates L, Caldas C, van't Veer L, Tutt A, Knappskog S, Tan BK, Jonkers J, Borg Å, Ueno NT, Sotiriou C, Viari A, Futreal PA, Campbell PJ, Span PN, Van Laere S, Lakhani SR, Eyfjord JE, Thompson AM, Birney E, Stunnenberg HG, van de Vijver MJ, Martens JW, Børresen-Dale AL, Richardson AL, Kong G, Thomas G, Stratton MR.

Nature. 2016 Jun 2;534(7605):47-54. doi: 10.1038/nature17676. Epub 2016 May 2.

25.

Mitochondrial DNA content in breast cancer: Impact on in vitro and in vivo phenotype and patient prognosis.

Weerts MJ, Sieuwerts AM, Smid M, Look MP, Foekens JA, Sleijfer S, Martens JW.

Oncotarget. 2016 May 17;7(20):29166-76. doi: 10.18632/oncotarget.8688.

26.

The advantage of laser-capture microdissection over whole tissue analysis in proteomic profiling studies.

De Marchi T, Braakman RB, Stingl C, van Duijn MM, Smid M, Foekens JA, Luider TM, Martens JW, Umar A.

Proteomics. 2016 May;16(10):1474-85. doi: 10.1002/pmic.201600004. Epub 2016 Apr 28.

PMID:
27030549
27.

GATA3 mRNA expression, but not mutation, associates with longer progression-free survival in ER-positive breast cancer patients treated with first-line tamoxifen for recurrent disease.

Liu J, Prager-van der Smissen WJ, Look MP, Sieuwerts AM, Smid M, Meijer-van Gelder ME, Foekens JA, Hollestelle A, Martens JW.

Cancer Lett. 2016 Jun 28;376(1):104-9. doi: 10.1016/j.canlet.2016.03.038. Epub 2016 Mar 24.

28.

Targeted MS Assay Predicting Tamoxifen Resistance in Estrogen-Receptor-Positive Breast Cancer Tissues and Sera.

De Marchi T, Kuhn E, Dekker LJ, Stingl C, Braakman RB, Opdam M, Linn SC, Sweep FC, Span PN, Luider TM, Foekens JA, Martens JW, Carr SA, Umar A.

J Proteome Res. 2016 Apr 1;15(4):1230-42. doi: 10.1021/acs.jproteome.5b01119. Epub 2016 Mar 18.

PMID:
26958999
29.

Global proteomic characterization of microdissected estrogen receptor positive breast tumors.

De Marchi T, Liu NQ, Sting C, Smid M, Tjoa M, Braakman RB, Luider TM, Foekens JA, Martens JW, Umar A.

Data Brief. 2015 Oct 8;5:399-402. doi: 10.1016/j.dib.2015.09.034. eCollection 2015 Dec.

30.

An 8-gene mRNA expression profile in circulating tumor cells predicts response to aromatase inhibitors in metastatic breast cancer patients.

Reijm EA, Sieuwerts AM, Smid M, Vries JB, Mostert B, Onstenk W, Peeters D, Dirix LY, Seynaeve CM, Jager A, de Jongh FE, Hamberg P, van Galen A, Kraan J, Jansen MP, Gratama JW, Foekens JA, Martens JW, Berns EM, Sleijfer S.

BMC Cancer. 2016 Feb 18;16:123. doi: 10.1186/s12885-016-2155-y.

31.

A Method to Correlate mRNA Expression Datasets Obtained from Fresh Frozen and Formalin-Fixed, Paraffin-Embedded Tissue Samples: A Matter of Thresholds.

Mustafa DA, Sieuwerts AM, Smid M, de Weerd V, van der Weiden M, Meijer-van Gelder ME, Martens JW, Foekens JA, Kros JM.

PLoS One. 2015 Dec 30;10(12):e0144097. doi: 10.1371/journal.pone.0144097. eCollection 2015.

32.

Annexin-A1 and caldesmon are associated with resistance to tamoxifen in estrogen receptor positive recurrent breast cancer.

De Marchi T, Timmermans AM, Smid M, Look MP, Stingl C, Opdam M, Linn SC, Sweep FC, Span PN, Kliffen M, van Deurzen CH, Luider TM, Foekens JA, Martens JW, Umar A.

Oncotarget. 2016 Jan 19;7(3):3098-110. doi: 10.18632/oncotarget.6521.

33.

Using second harmonic generation to predict patient outcome in solid tumors.

Burke K, Smid M, Dawes RP, Timmermans MA, Salzman P, van Deurzen CH, Beer DG, Foekens JA, Brown E.

BMC Cancer. 2015 Nov 24;15:929. doi: 10.1186/s12885-015-1911-8.

34.

Understanding drugs in breast cancer through drug sensitivity screening.

Uhr K, Prager-van der Smissen WJ, Heine AA, Ozturk B, Smid M, Göhlmann HW, Jager A, Foekens JA, Martens JW.

Springerplus. 2015 Oct 15;4:611. doi: 10.1186/s40064-015-1406-8. eCollection 2015.

35.

4-protein signature predicting tamoxifen treatment outcome in recurrent breast cancer.

De Marchi T, Liu NQ, Stingl C, Timmermans MA, Smid M, Look MP, Tjoa M, Braakman RB, Opdam M, Linn SC, Sweep FC, Span PN, Kliffen M, Luider TM, Foekens JA, Martens JW, Umar A.

Mol Oncol. 2016 Jan;10(1):24-39. doi: 10.1016/j.molonc.2015.07.004. Epub 2015 Aug 7.

36.

Clinical Relevance of Targeting the Gastrin-Releasing Peptide Receptor, Somatostatin Receptor 2, or Chemokine C-X-C Motif Receptor 4 in Breast Cancer for Imaging and Therapy.

Dalm SU, Sieuwerts AM, Look MP, Melis M, van Deurzen CH, Foekens JA, de Jong M, Martens JW.

J Nucl Med. 2015 Oct;56(10):1487-93. doi: 10.2967/jnumed.115.160739. Epub 2015 Aug 6.

37.

Carcinoma in situ to invasive breast cancer.

van Deurzen CH, Foekens JA.

Oncoscience. 2015 Jun 17;2(6):570-1. eCollection 2015. No abstract available.

38.

Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells.

Onstenk W, Sieuwerts AM, Kraan J, Van M, Nieuweboer AJ, Mathijssen RH, Hamberg P, Meulenbeld HJ, De Laere B, Dirix LY, van Soest RJ, Lolkema MP, Martens JW, van Weerden WM, Jenster GW, Foekens JA, de Wit R, Sleijfer S.

Eur Urol. 2015 Dec;68(6):939-45. doi: 10.1016/j.eururo.2015.07.007. Epub 2015 Jul 15.

PMID:
26188394
39.

Gene expression profiles of circulating tumor cells versus primary tumors in metastatic breast cancer.

Onstenk W, Sieuwerts AM, Weekhout M, Mostert B, Reijm EA, van Deurzen CH, Bolt-de Vries JB, Peeters DJ, Hamberg P, Seynaeve C, Jager A, de Jongh FE, Smid M, Dirix LY, Kehrer DF, van Galen A, Ramirez-Moreno R, Kraan J, Van M, Gratama JW, Martens JW, Foekens JA, Sleijfer S.

Cancer Lett. 2015 Jun 28;362(1):36-44. doi: 10.1016/j.canlet.2015.03.020. Epub 2015 Mar 19.

PMID:
25797316
40.

Tumor cell migration screen identifies SRPK1 as breast cancer metastasis determinant.

van Roosmalen W, Le Dévédec SE, Golani O, Smid M, Pulyakhina I, Timmermans AM, Look MP, Zi D, Pont C, de Graauw M, Naffar-Abu-Amara S, Kirsanova C, Rustici G, Hoen PA, Martens JW, Foekens JA, Geiger B, van de Water B.

J Clin Invest. 2015 Apr;125(4):1648-64. doi: 10.1172/JCI74440. Epub 2015 Mar 16.

41.

Int6 reduction activates stromal fibroblasts to enhance transforming activity in breast epithelial cells.

Suo J, Medina D, Herrera S, Zheng ZY, Jin L, Chamness GC, Contreras A, Gutierrez C, Hilsenbeck S, Umar A, Foekens JA, Hanash S, Schiff R, Zhang XH, Chang EC.

Cell Biosci. 2015 Mar 8;5:10. doi: 10.1186/s13578-015-0001-6. eCollection 2015.

42.

Decreased expression of ABAT and STC2 hallmarks ER-positive inflammatory breast cancer and endocrine therapy resistance in advanced disease.

Jansen MP, Sas L, Sieuwerts AM, Van Cauwenberghe C, Ramirez-Ardila D, Look M, Ruigrok-Ritstier K, Finetti P, Bertucci F, Timmermans MM, van Deurzen CH, Martens JW, Simon I, Roepman P, Linn SC, van Dam P, Kok M, Lardon F, Vermeulen PB, Foekens JA, Dirix L, Berns EM, Van Laere S.

Mol Oncol. 2015 Jun;9(6):1218-33. doi: 10.1016/j.molonc.2015.02.006. Epub 2015 Mar 4.

43.

DC-SCRIPT is a novel regulator of the tumor suppressor gene CDKN2B and induces cell cycle arrest in ERα-positive breast cancer cells.

Ansems M, Søndergaard JN, Sieuwerts AM, Looman MW, Smid M, de Graaf AM, de Weerd V, Zuidscherwoude M, Foekens JA, Martens JW, Adema GJ.

Breast Cancer Res Treat. 2015 Feb;149(3):693-703. doi: 10.1007/s10549-015-3281-y. Epub 2015 Feb 8.

44.

mRNA expression profiles in circulating tumor cells of metastatic colorectal cancer patients.

Mostert B, Sieuwerts AM, Bolt-de Vries J, Kraan J, Lalmahomed Z, van Galen A, van der Spoel P, de Weerd V, Ramírez-Moreno R, Smid M, Verhoef C, IJzermans JN, Gratama JW, Sleijfer S, Foekens JA, Martens JW.

Mol Oncol. 2015 Apr;9(4):920-32. doi: 10.1016/j.molonc.2015.01.001. Epub 2015 Jan 21.

45.

Proper genomic profiling of (BRCA1-mutated) basal-like breast carcinomas requires prior removal of tumor infiltrating lymphocytes.

Massink MP, Kooi IE, van Mil SE, Jordanova ES, Ameziane N, Dorsman JC, van Beek DM, van der Voorn JP, Sie D, Ylstra B, van Deurzen CH, Martens JW, Smid M, Sieuwerts AM, de Weerd V, Foekens JA, van den Ouweland AM, van Dyk E, Nederlof PM, Waisfisz Q, Meijers-Heijboer H.

Mol Oncol. 2015 Apr;9(4):877-88. doi: 10.1016/j.molonc.2014.12.012. Epub 2015 Jan 13.

46.

Integrative analysis of genomics and proteomics data on clinical breast cancer tissue specimens extracted with acid guanidinium thiocyanate-phenol-chloroform.

Braakman RB, Bezstarosti K, Sieuwerts AM, de Weerd V, van Galen AM, Stingl C, Luider TM, Timmermans MA, Smid M, Martens JW, Foekens JA, Demmers JA, Umar A.

J Proteome Res. 2015 Mar 6;14(3):1627-36. doi: 10.1021/acs.jproteome.5b00046. Epub 2015 Feb 2.

PMID:
25611981
47.

Are immune signatures a worthwhile tool for decision making in early-stage human epidermal growth factor receptor 2-positive breast cancer?

Foekens JA, Martens JW, Sleijfer S.

J Clin Oncol. 2015 Mar 1;33(7):673-5. doi: 10.1200/JCO.2014.59.5058. Epub 2015 Jan 20. No abstract available.

PMID:
25605833
48.

Improved Circulating Tumor Cell Detection by a Combined EpCAM and MCAM CellSearch Enrichment Approach in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy.

Onstenk W, Kraan J, Mostert B, Timmermans MM, Charehbili A, Smit VT, Kroep JR, Nortier JW, van de Ven S, Heijns JB, Kessels LW, van Laarhoven HW, Bos MM, van de Velde CJ, Gratama JW, Sieuwerts AM, Martens JW, Foekens JA, Sleijfer S.

Mol Cancer Ther. 2015 Mar;14(3):821-7. doi: 10.1158/1535-7163.MCT-14-0653. Epub 2014 Dec 31.

49.

Gene expression profiles in circulating tumor cells to predict prognosis in metastatic breast cancer patients.

Mostert B, Sieuwerts AM, Kraan J, Bolt-de Vries J, van der Spoel P, van Galen A, Peeters DJ, Dirix LY, Seynaeve CM, Jager A, de Jongh FE, Hamberg P, Stouthard JM, Kehrer DF, Look MP, Smid M, Gratama JW, Foekens JA, Martens JW, Sleijfer S.

Ann Oncol. 2015 Mar;26(3):510-6. doi: 10.1093/annonc/mdu557. Epub 2014 Dec 3.

PMID:
25471333
50.

Growth and metastatic behavior of molecularly well-characterized human breast cancer cell lines in mice.

Riaz M, Setyono-Han B, Timmermans MA, Trapman AM, Bolt-de Vries J, Hollestelle A, Janssens RC, Look MP, Schutte M, Foekens JA, Martens JW.

Breast Cancer Res Treat. 2014 Nov;148(1):19-31. doi: 10.1007/s10549-014-3142-0. Epub 2014 Sep 30.

PMID:
25266129

Supplemental Content

Loading ...
Support Center